Krystal Biotech Inc
KRYSHealthcare|Biotechnology|USA
$365.80
-5.27 (-1.42%)
DCF (FCF)
$31.98
Tangible Book
$43.37
Graham Number
$85.44
Earnings Power
$26.08
Clinical Trials (22)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07016750 A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa | Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | P3 | Recruiting | 16 | RCT, Double-blind | KB803, Placebo |
| NCT06228326 A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Lung Cancer, Non-small Cell, Lung Cancer Metastatic | P1P2 | Recruiting | 250 | Open-label | KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy, Docetaxel |
| NCT06999733 A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis | Neurotrophic Keratitis | P1P2 | Recruiting | 60 | RCT, Double-blind | KB801, Placebo |
| NCT06724900 A Study Assessing KB304 for the Treatment of Wrinkles in Women | Wrinkles in Decolletage, Pigmentation | P1P2 | Active | 19 | RCT, Double-blind | KB304, 0.9% Normal Saline (NS) |
| NCT05970497 A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | Cancer, Melanoma Stage III | P1P2 | Recruiting | 240 | Open-label | KB707, Opdualag, KEYTRUDA ®( Pembrolizumab) |
| NCT06049082 A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency | Alpha 1-Antitrypsin Deficiency | P1 | Recruiting | 15 | Open-label | KB408 (Nebulization) |
| NCT05504837 A Study Assessing KB407 for the Treatment of Cystic Fibrosis | Cystic Fibrosis | P1 | Recruiting | 20 | Open-label | KB407 (Nebulization) |
| NCT04540900 A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions | Skin Roughness, Wrinkle | P1 | Active | 85 | Open-label | KB301 |
| NCT06563414 A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB) | Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive | Recruiting | 40 | — | — | |
| NCT04917887 Long-Term Follow-up Protocol | Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | Recruiting | 50 | — | — | |
| NCT04004169 Closed-Loop Deep Brain Stimulation for Major Depression | Major Depressive Disorder | N/A | Recruiting | 12 | RCT, Double-blind | — |
| NCT03217110 Cerebellar Stimulation and Cognitive Control | Schizophrenia, Autism Spectrum Disorder | N/A | Recruiting | 200 | RCT, Single-blind | — |
| NCT07127913 Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression | Bipolar II Disorder, Bipolar II Disorder, Most Recent Episode Major Depressive | N/A | Recruiting | 10 | RCT, Double-blind | — |
| NCT04917874 A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa | Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | P3 | Completed | 47 | Open-label | Open Label Topical Beremagene Geperpavec (B-VEC) |
| NCT04491604 Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB | Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa | P3 | Completed | 31 | RCT, Double-blind | Topical Beremagene Geperpavec |
| NCT03536143 A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients | Dystrophic Epidermolysis Bullosa | P1P2 | Completed | 12 | RCT, Open-label | Topical beremagene geperpavec, Placebo gel |
| NCT05735158 Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) | Autosomal Recessive Ichthyosis | P2 | Unknown | 15 | RCT, Double-blind | KB105 |
| NCT04047732 Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) | TGM-1 Related Autosomal Recessive Congenital Ichthyosis | P1P2 | Unknown | 6 | Open-label | KB105 |
| NCT01837862 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | Pilomyxoid Astrocytoma, Pilocytic Astrocytoma | P1P2 | Completed | 36 | Open-label | Mebendazole, Vincristine, Carboplatin, Temozolomide, Bevacizumab, Irinotecan |
| NCT05095246 A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis | Cystic Fibrosis | P1 | Withdrawn | — | Open-label | KB407 (Nebulization) |
| NCT02218775 FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor Phase 1 Study | Anxiety Disorders | P1 | Withdrawn | — | Open-label | LY2456302 |
| NCT04214002 The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB) | Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | Withdrawn | — | — | — |